Data were provided at the 11th International Meeting on Malignant Lymphoma in Lugano, Switzerland . The authors referred to a pattern of ‘progressive resistance’ as a continual decrease of responses and progression-free survival in patients in the second-series treatment setting and then with each subsequent therapy – a pattern often seen in hematologic malignancies and solid tumors. This analysis not only provides insight into the occurrence of progressive level of resistance in the treatment of individuals with peripheral T-cell lymphoma, but also suggests that FOLOTYN may reverse the pattern of progressive resistance seen in patients with relapsed or refractory peripheral T-cell lymphoma, stated Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics.We are deeply honored to receive the Varro E. Tyler Award from the American Botanical Council, said Dahbour, and can continue Prof. Tyler's passion for botanical analysis and discovery. Earlier recipients of the ABC Tyler Award consist of Horphag Study of Switzerland for 2012, Bioforce AG of Switzerland for 2011, New Chapter, Inc. Of the United States in 2010 2010, Bionorica AG of Germany for 2009, Indena SpA of Italy for 2008, and Dr. Willmar Schwabe Pharmaceuticals of Germany for 2007. The ABC Varro E. Tyler Commercial Investment in Phytomedicinal Analysis Award was announced at the 9th Annual ABC Botanical Special event and Awards Ceremony on March 6 in Anaheim, California.